Not getting enough sleep does more than make you tired. Here’s how short nights can quietly raise your blood pressure, and ...

AstraZeneca's aldosterone synthase inhibitor baxdrostat reduced blood pressure by 14 mmHg over 12 weeks, the pharma has said ...

A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.

Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 – – Conference call today ...

CKD prevalence has more than doubled since 1990, with 788 million adults affected in 2023, highlighting a significant global health challenge. The disease is a major contributor to cardiovascular ...

The observational study conducted by Albert and colleagues assessed 43,625 patients hospitalized with heart failure in the 241 hospitals participating in the Get With The Guidelines–Heart Failure ...

AstraZeneca has announced positive results from its Bax24 trial of baxdrostat, an investigational treatment for hypertension, ...

Not taking enough vitamin D can cause more harm than you’ve heard. Take the risk to heart health, for example. But no worries ...

Discover the complexities of Addison's disease in dogs, including diagnosis, treatment options, and management strategies for ...

In the Bax24 study reported at the AHA, aldosterone synthase inhibitor (ASI) baxdrostat achieved a 16.6 mm Hg reduction in 24 ...

Balcinrenone is similar to finerenone (Kerendia), which is also a nonsteroidal MRA and was approved for the slowing of ...

AstraZeneca and Sun Pharma will jointly market SZC, a key hyperkalaemia drug for CKD and heart failure patients, under ...